115 related articles for article (PubMed ID: 26808665)
1. Adaptive responses to antibody based therapy.
Rodems TS; Iida M; Brand TM; Pearson HE; Orbuch RA; Flanigan BG; Wheeler DL
Semin Cell Dev Biol; 2016 Feb; 50():153-63. PubMed ID: 26808665
[TBL] [Abstract][Full Text] [Related]
2. Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.
Lee JM; Lee SH; Hwang JW; Oh SJ; Kim B; Jung S; Shim SH; Lin PW; Lee SB; Cho MY; Koh YJ; Kim SY; Ahn S; Lee J; Kim KM; Cheong KH; Choi J; Kim KA
Oncogene; 2016 Aug; 35(34):4437-46. PubMed ID: 26853467
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
4. [Non-canonical Activation of Receptor Tyrosine Kinases in Cancer Progression].
Sakurai H
Yakugaku Zasshi; 2017; 137(2):141-144. PubMed ID: 28154322
[TBL] [Abstract][Full Text] [Related]
5. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
7. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.
Hsu JL; Hung MC
Cancer Metastasis Rev; 2016 Dec; 35(4):575-588. PubMed ID: 27913999
[TBL] [Abstract][Full Text] [Related]
8. Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.
LaVallee TM; Alvarado D; Garton AJ; Trombetta ES; Gedrich R; McMahon G
Crit Rev Oncog; 2015; 20(5-6):485-508. PubMed ID: 27279243
[TBL] [Abstract][Full Text] [Related]
9. Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.
Weber H; Müller D; Müller M; Ortiz A; Birkle M; Umber S; Ketterer C; Siedentopf O; Feger D; Totzke F; Kubbutat M; Schaechtele C; Ballmer-Hofer K; Ehlert JE; Graeser R
J Biomol Screen; 2014 Dec; 19(10):1350-61. PubMed ID: 25260782
[TBL] [Abstract][Full Text] [Related]
10. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
11. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick E; Bange J; Ullrich A
Endocr Relat Cancer; 2001 Sep; 8(3):161-73. PubMed ID: 11566607
[TBL] [Abstract][Full Text] [Related]
13. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
14. Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment.
Yamanashi Y; Tezuka T; Yokoyama K
J Biochem; 2012 Apr; 151(4):353-9. PubMed ID: 22343747
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
16. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
17. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis.
Templeton AJ; Diez-Gonzalez L; Ace O; Vera-Badillo F; Seruga B; Jordán J; Amir E; Pandiella A; Ocaña A
Cancer Treat Rev; 2014 Oct; 40(9):1048-55. PubMed ID: 25217796
[TBL] [Abstract][Full Text] [Related]
19. Targeting HER1/EGFR: a molecular approach to cancer therapy.
Arteaga C
Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
[TBL] [Abstract][Full Text] [Related]
20. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
